When DNA damage is overwhelmed by application of DDAs, disrupting the interaction between ZCCHC4 and AL133467.2 will effectively enhance the cancer cells response to chemotherapeutic practice, or even immunotherapeutic practice, considering DDR has also emerged as an important determinant of tumor immunogenicity.47 The gene discussed is ZCCHC4; the disease is neoplasm.